Adverse events risk associated with bevacizumab addition to breast cancer chemotherapy: a meta-analysis.

@article{Corts2012AdverseER,
  title={Adverse events risk associated with bevacizumab addition to breast cancer chemotherapy: a meta-analysis.},
  author={Javier Bascu{\~n}{\'a}n Cort{\'e}s and Virginia Calvo and Natalia Ram{\'i}rez-Merino and Joyce O'Shaughnessy and Adam Brufsky and N Cole Robert and M. Fuentesanta Espinosa Vidal and Eva Guerra Mu{\~n}oz and Javier Blanco P{\'e}rez and Shaheenah Dawood and Cristina Band{\'i}n Saura and Serena Di Cosimo and Antonio Gonz{\'a}lez-Mart{\'i}n and Meritxell Bellet and Oliveira T{\^a}nia Silva and David L. Miles and Antoni Llombart and Jos{\'e} Baselga},
  journal={Annals of oncology : official journal of the European Society for Medical Oncology},
  year={2012},
  volume={23 5},
  pages={
          1130-7
        }
}
BACKGROUND Bevacizumab is a monoclonal antibody against vascular endothelial growth factor with the ability to increase progression-free survival in metastatic breast cancer (MBC). A systematic review and meta-analysis was conducted to determine the risk of the most clinically relevant adverse outcomes associated with the use of bevacizumab in the treatment of breast cancer. PATIENTS AND METHODS We included phase III clinical trials that used bevacizumab alone or in combination with… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 26 CITATIONS

Targeted anti-vascular therapies for ovarian cancer: current evidence

  • British Journal of Cancer
  • 2013
VIEW 3 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

Application of radiation technology in vaccines development

  • Clinical and experimental vaccine research
  • 2015
VIEW 1 EXCERPT
CITES BACKGROUND

Bevacizumab in clinical practice.

VIEW 1 EXCERPT
CITES BACKGROUND

References

Publications referenced by this paper.
SHOWING 1-10 OF 26 REFERENCES

Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer.

  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2005
VIEW 4 EXCERPTS
HIGHLY INFLUENTIAL

Avastin (Bevacizumab) FDA Drug Label 2008: http:// www.accessdata.fda.gov/drugsatfda_docs/label/2009/125085s0169lbl.pdf

Genentech, Inc
  • Date last accessed)
  • 2011

Similar Papers

Loading similar papers…